Insights
Statistical Insights: Designing clinical studies for success and not failure
Why aren’t biostatisticians involved earlier in the clinical trial design process?
Statistical Insights: Going Synthetic with Real-World Data
Real-world data has the potential to have a positive impact on the treatment of serious conditions, providing much-needed insights into the health and treatment of patients in an everyday setting…
Statistical Insights: The liberation of real-world data
The costs and complexities associated with drug development are fuelling the drive for more efficient healthcare delivery…
Statistical Insights: Belfast is where Exploristics’ heart is
Why Belfast is a great place to set up a life science business.
Statistical Insights: Why Getting Smaller Doesn’t Mean Thinking Smaller
In the wake of a tumultuous 2020, I have taken the opportunity to reflect on the progress Exploristics has made as a company and reappraise my reasons for setting it up.
Statistical Insights: Clinical trials after COVID-19
The challenges faced by the Pharmaceutical Industry have been well documented…
Statistical Insights: COVID-19
The COVID-19 pandemic has demonstrated the importance of science and the dedication of scientists in overcoming the challenges that we face…
Interviews
The Effective Statistician
Exploristics CEO, Aiden Flynn, joins Alexander Schacht on his Effective Statistician podcast to discuss the power of simulation in designing clinical studies.
Common Causes of Clinical Trial Failures
A discussion with Matthew Cardinal from Halloran Consulting Group.
People Always, Patients Sometimes
Exploristics’ CEO discusses how data simulation studies can reduce the risk and costs of clinical trials.
Statistical Insights: Designing clinical studies for success and not failure
Why aren’t biostatisticians involved earlier in the clinical trial design process?
Statistical Insights: Going Synthetic with Real-World Data
Real-world data has the potential to have a positive impact on the treatment of serious conditions, providing much-needed insights into the health and treatment of patients in an everyday setting…
Statistical Insights: The liberation of real-world data
The costs and complexities associated with drug development are fuelling the drive for more efficient healthcare delivery…
Statistical Insights: Belfast is where Exploristics’ heart is
Why Belfast is a great place to set up a life science business.
Statistical Insights: Why Getting Smaller Doesn’t Mean Thinking Smaller
In the wake of a tumultuous 2020, I have taken the opportunity to reflect on the progress Exploristics has made as a company and reappraise my reasons for setting it up.
Statistical Insights: Clinical trials after COVID-19
The challenges faced by the Pharmaceutical Industry have been well documented…
Statistical Insights: COVID-19
The COVID-19 pandemic has demonstrated the importance of science and the dedication of scientists in overcoming the challenges that we face…
Interviews
The Effective Statistician
Exploristics CEO, Aiden Flynn, joins Alexander Schacht on his Effective Statistician podcast to discuss the power of simulation in designing clinical studies.
Common Causes of Clinical Trial Failures
A discussion with Matthew Cardinal from Halloran Consulting Group.
People Always, Patients Sometimes
Exploristics’ CEO discusses how data simulation studies can reduce the risk and costs of clinical trials.
White Papers
White Papers
Better Adherence, Higher Engagement:
Finding The Clinical Trials Sweet Spot
Clinical trial sponsors and clinical research organizations must work through an ever-expanding set of challenges to ensure their studies of new drugs produce valid results. And they must do so while strictly managing costs and timelines. As more trials make use of inhome settings, digital technologies and realtime patient data, the pressure increases to efficiently manage a process that’s dramatically different from the traditional methods of direct observation inside the walls of a clinic.
Engaging With Regulators On Novel Statistical Approaches To Clinical Development
The Pharmaceutical Industry is undergoing significant change as it faces extreme pressure to deliver new treatments to market at a time of increased spending in R&D. Multiple economic pressures are being exerted on the industry, ranging from an impending patent cliff, a decrease in income due to greater competition from generics and biosimilars, to demands on drug pricing by governments.
Want to find out more? Get in touch.